A specific nano antibody for detecting Brucella Bp26 and its application

By developing specific nano-antibody for Brucella Bp26, the complex cross-reaction and operation of existing detection methods are solved, and efficient and accurate detection of brucella disease is achieved, suitable for competing ELISA methods.

CN116789815BActive Publication Date: 2024-11-15NORTHWEST A & F UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310766951.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-27
Publication Date
2024-11-15
Estimated Expiration
2043-06-27

AI Technical Summary

Technical Problem

The existing brucellosis detection methods have cross-reaction problems, resulting in insufficient detection specificity and accuracy, and pathogenic diagnosis needs to be carried out in a biosafety laboratory and is complex and time-consuming.

Method used

Develop specific nano-antibody for detection of Brucella Bp26, including nano-antibody Nb1, Nb2, Nb3, Nb4, Nb5, through recombinant protein induced expression and purification, combined with phage panning and ELISA detection, to construct a competing ELISA method to improve Detection specificity and accuracy.

Benefits of technology

The specific identification and blocking of Brucella Bp26 is achieved, the detection process is simplified, the specificity and accuracy of the detection is improved, the cost and time is reduced, and it is suitable for the competitive ELISA method with simple operation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116789815B_ABST
    Figure CN116789815B_ABST
Patent Text Reader

Abstract

The present invention provides a method for preparing a specific nano antibody for detecting Brucella Bp26. The method uses Bp26 recombinant protein to screen in a Brucella phage display library to obtain nucleotide and amino acid sequences of five Bp26-specific nano antibodies, wherein the five Bp26-specific nano antibodies include nano antibody Nb1, nano antibody Nb2, nano antibody Nb3, nano antibody Nb4, and nano antibody Nb5. The present invention also provides a method for constructing an expression vector of the Bp26-specific nano antibody, and the application of the expression vector constructed by the construction method. The fusion protein expressed by the expression vector can be used to establish a simple and rapid competitive ELISA method to detect Brucella Bp26 antibodies in serum. The nano antibody of the present invention has high affinity, can specifically identify Brucella outer membrane protein Bp26, and effectively block the binding of Brucella positive serum to Bp26.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of immune detection, and specifically relates to a specific nano antibody for detecting Brucella Bp26 and an application thereof. Background Art

[0002] Brucellosis is a zoonotic infectious disease caused by Brucella, referred to as brucellosis. The World Organization for Animal Health (OIE) lists it as a reportable animal infectious disease, and my country lists it as a Category II animal epidemic disease. In recent years, brucellosis has shown a clear upward trend in China, causing huge economic losses to the breeding industry and seriously threatening human food safety and public health safety.

[0003] Detection of Brucella pathogens and specific antibodies is the key to the prevention and control of brucellosis. The diagnostic methods of brucellosis include etiological diagnosis and serological diagnosis. Etiological diagnostic methods mainly include pathogen isolation and molecular diagnostic methods (conventional PCR, real-time quantitative PCR, LAMP, AMOS-PCR, etc.), but etiological diagnostic methods need to be completed in a biosafety laboratory, and operators must undergo professional training, and the detection time is long. The current serological detection methods are mainly based on Brucella lipopolysaccharide chains, but some Gram-negative bacteria (Escherichia coli O157:H7, Yersinia enterocolitica O:9, etc.) have the same antigenic epitopes as Brucella lipopolysaccharide, and the resulting cross-reactions will affect the specificity of serological detection to a certain extent. Therefore, it is necessary to identify Brucella-specific immunogenic proteins and develop diagnostic methods to replace LPS based on them.

[0004] Bp26 protein, also known as Omp28, is present in all Brucella strains and is highly conserved among the six classic species of Brucella. It is a dominant immunogen in Brucella-infected cattle, sheep, goats and humans. Many reports have shown that it can be used as a target protein for serological testing with a high accuracy rate. Therefore, Bp26 was selected as an antigen, and its specific nanoantibodies were screened to establish a simple and rapid competitive ELISA method to further improve the specificity and accuracy of the test, which is very necessary for improving the prevention and control technology of brucellosis. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a specific nano antibody for detecting Brucella Bp26 and its application in view of the deficiencies of the above-mentioned prior art. The specific nano antibody includes nano antibody Nb1, nano antibody Nb2, nano antibody Nb3, nano antibody Nb4, and nano antibody Nb5, which can specifically recognize Brucella outer membrane protein Bp26 and effectively block the binding of Brucella positive serum with Bp26.

[0006] To solve the above technical problems, the technical solution adopted by the present invention is: a method for preparing a specific nano antibody for detecting Brucella Bp26, the method comprising:

[0007] Step 1: Induced expression of Bp26 recombinant protein

[0008] The pET32a-Bp26 bacterial solution was inoculated into LB-Amp medium at a ratio of 1 / 1000 and cultured at 37°C and 200 r / min until the logarithmic growth phase. The activated bacterial solution was then inoculated into 200 mL of new LB-Amp medium and cultured at 37°C and 200 r / min until the OD 600 The cell suspension was 0.6, 200 μL 1 mM IPTG was added for induction, and the suspension was cultured at 16°C and 200 r / min for 24 h; the suspension was centrifuged at 4°C and 8000 r / min for 15 min, the supernatant was discarded, the bacteria were resuspended with 1 / 20 volume of buffer A, and then the bacterial suspension was broken by ultrasound for 3 s, 3 s interval, 30% power, and 20 min; the suspension was centrifuged at 4°C and 12000 r / min for 10 min to separate the supernatant and the precipitate;

[0009] Step 2: Purification of Bp26 protein

[0010] The HIS tag purification gravity column was drained of the protective liquid, and 10 column volumes of buffer A were added to balance the gravity column; the supernatant obtained in step 1 was filtered with a 0.45μM filter, added to the gravity column, contacted for 30 minutes, the flow rate was adjusted to 0.5mL / min, and the flow-through was collected; 5 to 10 volumes of buffer A were added to wash the column until the A280 absorbance reached the baseline level; 5 to 10 volumes of buffer B were added to wash the column to remove non-specifically adsorbed impurities and collect the effluent until the A280 absorbance reached the baseline level; 0.1 to 0.5 volumes of Elution buffer were used for elution, and the eluate was collected in sections until the A280 absorbance reached the baseline level, and SDS-PAGE was performed; the eluted protein was dialyzed for 36 hours, and the dialysate was replaced every 12 hours. After the dialysis, PEG8000 was used for concentration, and the protein concentration was determined. After aliquoting, it was frozen at -80°C;

[0011] Step 3: Selection of Bp26-specific phage

[0012] The Bp26 protein purified in step 2 was coated on a 96-well ELISA plate at 10 μg / well, repeated for 3 wells, and a PBS control well was set up, and the plate was coated overnight at 4°C; the coating solution was discarded, and the plate was washed three times with PBST for 5 min each time, and blocked with 2.5% skim milk powder at 37°C for 1 h; the blocking solution was discarded, and the plate was washed three times with PBST for 10 min each time, and 5×10 10PFU / well phage, incubate at 37℃ for 2h; discard the liquid, wash five times with PBST, 5min each time; add 100μL 0.1M triethylamine, let stand at room temperature for 10min, then aspirate the liquid and neutralize with 100μL 1MTris-HCl; take 0.2mL of the selected product and inoculate it into 200mL 2×YT / AMP-GLU medium, culture at 37℃ to the logarithmic growth phase, add 20MOI helper phage M13K07 and mix evenly, incubate at 37℃ for 30min, centrifuge at 3000g at room temperature for 15min, discard the supernatant, resuspend the precipitate with 200mL 2×YT / AMP-KAN medium, and culture at 37℃ for 12h , centrifuged at 3000g for 30min, collected the supernatant, added 1 / 5 volume of PEG / NaCl solution precooled to 4°C, and incubated on ice for 6-8h; 3500g, centrifuged at 4°C for 30min, discarded the supernatant, and resuspended the precipitate with 1mL PBS solution; incubated overnight on a 4°C shaker, centrifuged at 4°C for 15min, collected the supernatant, and used TG1 to determine the titer of the recombinant phage; subsequently coated with 10 and 5μg / well of Bp26 protein, and performed the second and third rounds of panning respectively; the preparation method of the PEG / NaCl solution is as follows: 200g PEG6000 and 146g NaCl are dissolved in water, the volume is fixed to 1L, and then sterilized by high pressure;

[0013] Step 4. Preparation of Nanobody Crude Extract

[0014] In the last round of selection in step 3, 96 phage monoclones were picked and added to 100 μL LB / AMP-GLU medium in a 96-well cell culture plate for 8 h at 37°C and 200 r / min. 10 μL was transferred to a 24-well cell culture plate with 1 mL TB medium per well and cultured at 37°C until OD 600 The concentration of IPTG was 0.6, and IPTG was added to a final concentration of 1 mM and cultured for 12 hours; the cells were centrifuged at 12000 r / min for 5 minutes, the cells were collected, and the cells were repeatedly frozen and thawed at -80°C and 37°C for three times to lyse the cells, 500 μL PBS was added to resuspend the cells, incubated at 4°C for 2 hours, and centrifuged at 12000 r / min for 5 minutes. The supernatant was collected as the crude extract of the nanobody;

[0015] Step 5: ELISA detection of crude nanoantibody extract

[0016] 2 μg / mL purified Bp26 recombinant protein and PBS were coated on a 96-well ELISA plate at 4°C overnight; washed three times with PBST for 5 minutes each time, blocked with 2.5% skimmed milk powder for 1 hour, and washed three times with PBST for 5 minutes each time; 100 μL of the crude nanoantibody extract obtained in step 4 was added, incubated at 37°C for 1 hour, and washed five times with PBST for 5 minutes each time; mouse anti-HA antibody diluted 1:3000 was added, incubated at 37°C for 1 hour, and washed three times with PBST for 5 minutes each time; HRP-labeled goat anti-mouse IgG was diluted 1:5000 and added to the wells, incubated at 37°C for 1 hour, and washed three times with PBST for 5 minutes each time; after washing, TMB colorimetric solution was added and incubated for 15 minutes, and the reaction was terminated with 3M H2SO4; the absorbance value of the ELISA reader was set to OD 450 , read the values ​​and analyze the results; select positive clones for sequencing and obtain five Bp26-specific nanobodies, which are named nanobody Nb1, nanobody Nb2, nanobody Nb3, nanobody Nb4, and nanobody Nb5;

[0017] The nucleotide sequence of the nanobody Nb1 is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2;

[0018] The nucleotide sequence of the nanobody Nb2 is shown in SEQ ID NO.3, and the amino acid sequence is shown in SEQ ID NO.4;

[0019] The nucleotide sequence of the nanobody Nb3 is shown in SEQ ID NO.5, and the amino acid sequence is shown in SEQ ID NO.6;

[0020] The nucleotide sequence of the nanobody Nb4 is shown in SEQ ID NO.7, and the amino acid sequence is shown in SEQ ID NO.8;

[0021] The nucleotide sequence of the nanobody Nb5 is shown in SEQ ID NO.9, and the amino acid sequence is shown in SEQ ID NO.10.

[0022] Preferably, the Nanobody Nb1, Nanobody Nb2, Nanobody Nb3, Nanobody Nb4 and Nanobody Nb5 each include four framework regions FR1, FR2, FR3, FR4 and three complementary determining regions CDR1, CDR2, CDR3, and the arrangement order of the four framework regions and the three complementary determining regions is FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4;

[0023] For the Nanobody Nb1: the amino acid sequence of the FR1 is shown in SEQ ID NO.11, the amino acid sequence of the FR2 is shown in SEQ ID NO.12, the amino acid sequence of the FR3 is shown in SEQ ID NO.13, the amino acid sequence of the FR4 is shown in SEQ ID NO.14, the amino acid sequence of the CDR1 is shown in SEQ ID NO.15, the amino acid sequence of the CDR2 is shown in SEQ ID NO.16, and the amino acid sequence of the CDR3 is shown in SEQ ID NO.17;

[0024] For the Nanobody Nb2: the amino acid sequence of the FR1 is shown in SEQ ID NO.18, the amino acid sequence of the FR2 is shown in SEQ ID NO.19, the amino acid sequence of the FR3 is shown in SEQ ID NO.20, the amino acid sequence of the FR4 is shown in SEQ ID NO.21, the amino acid sequence of the CDR1 is shown in SEQ ID NO.22, the amino acid sequence of the CDR2 is shown in SEQ ID NO.23, and the amino acid sequence of the CDR3 is shown in SEQ ID NO.24;

[0025] For the Nanobody Nb3: the amino acid sequence of the FR1 is shown in SEQ ID NO.25, the amino acid sequence of the FR2 is shown in SEQ ID NO.26, the amino acid sequence of the FR3 is shown in SEQ ID NO.27, the amino acid sequence of the FR4 is shown in SEQ ID NO.28, the amino acid sequence of the CDR1 is shown in SEQ ID NO.29, the amino acid sequence of the CDR2 is shown in SEQ ID NO.30, and the amino acid sequence of the CDR3 is shown in SEQ ID NO.31;

[0026] For the Nanobody Nb4: the amino acid sequence of the FR1 is shown in SEQ ID NO.32, the amino acid sequence of the FR2 is shown in SEQ ID NO.33, the amino acid sequence of the FR3 is shown in SEQ ID NO.34, the amino acid sequence of the FR4 is shown in SEQ ID NO.35, the amino acid sequence of the CDR1 is shown in SEQ ID NO.36, the amino acid sequence of the CDR2 is shown in SEQ ID NO.37, and the amino acid sequence of the CDR3 is shown in SEQ ID NO.38;

[0027] For the Nanobody Nb5: the amino acid sequence of the FR1 is shown in SEQ ID NO.39, the amino acid sequence of the FR2 is shown in SEQ ID NO.40, the amino acid sequence of the FR3 is shown in SEQ ID NO.41, the amino acid sequence of the FR4 is shown in SEQ ID NO.42, the amino acid sequence of the CDR1 is shown in SEQ ID NO.43, the amino acid sequence of the CDR2 is shown in SEQ ID NO.44, and the amino acid sequence of the CDR3 is shown in SEQ ID NO.45.

[0028] The present invention also provides a method for constructing an expression vector of a specific nano antibody for detecting Brucella Bp26 prepared by the above method, the method comprising:

[0029] The gene sequence of the Bp26-specific nanoantibody was inserted into the pCMV-HRP vector through the two restriction sites of PstI and NotI, and the recombinant plasmids were constructed respectively. The correctness of the recombinant plasmids was verified by PCR and sequencing. The endotoxin-free pCMV-Nb1-HRP, pCMV-Nb2-HRP, pCMV-Nb3-HRP, pCMV-Nb4-HRP, and pCMV-Nb5-HRP recombinant plasmids were extracted respectively. HEK-293T cells were plated in 12-well plates. When the cells were 70% to 80% full, the cells were plated using Thermo The recombinant plasmid was mixed with TurboFect transfection reagent and transfected into HEK-293T cells. After 72 hours, the supernatant was collected to obtain Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP fusion proteins, respectively; the Bp26-specific nanoantibodies include nanoantibodies Nb1, nanoantibodies Nb2, nanoantibodies Nb3, nanoantibodies Nb4, and nanoantibodies Nb5;

[0030] The present invention also provides an application of an expression vector constructed by the construction method, and the fusion protein expressed by the expression vector can be used to construct a competitive ELISA method to detect Brucella Bp26 antibodies;

[0031] Preferably, the competitive ELISA method is constructed by the following steps:

[0032] S1. Chessboard method to determine the optimal antigen-antibody working concentration

[0033] S101, coating antigen: dilute the Bp26 protein to 1, 2, and 4 μg / mL and coat it on the ELISA plate at 4°C overnight;

[0034] S102, blocking: wash three times with PBST solution, 5 min each time, add 100 μL 2.5% skim milk powder, block at 37°C for 1 h, and wash three times with PBST;

[0035] S103, incubation with antibodies: dilute the fusion protein expressed by the nanobody expression vector by 2, 4, 8, 16, 32, 64, and 128 times, add to the ELISA plate, incubate at 37°C for 1 h, and wash three times with PBST;

[0036] S104, color development and termination: add 100 μL TMB color development solution and incubate at room temperature for 15 min, terminate the reaction with 50 μL 3M sulfuric acid, read the absorbance at 450 nm, analyze the results, and determine the optimal antigen and antibody dilution concentrations for competitive ELISA;

[0037] Among them, the fusion protein expressed by the nanobody expression vector described in S103 is the fusion protein with the highest affinity to the Bp26 protein among Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP;

[0038] S2. Determine serum dilution for competitive ELISA method

[0039] S201, coating antigen: coat the Bp26 protein with the optimal antigen dilution concentration obtained in S1 onto a 96-well ELISA plate at 4°C overnight;

[0040] S202, blocking: wash three times with PBST solution, add 100 μL 2.5% skim milk powder, block at 37°C for 1 h, and wash three times with PBST;

[0041] S203, dilute serum: select four portions of positive serum and negative serum, dilute them at 1:5, 1:10, 1:15, and 1:20, and mix them with the fusion protein expressed by the nanobody expression vector diluted with the optimal antibody dilution obtained in S1, add 100 μL of the mixture to each well, incubate at 37°C for 1 hour, and wash three times with PBST;

[0042] S204, color development and termination: incubate with TMB color development solution at room temperature for 15 minutes, and terminate the reaction with 3M sulfuric acid; read the absorbance at 450 nm, analyze the results, and determine the optimal serum dilution for the competitive ELISA method;

[0043] S3. Establishment of competitive ELISA method based on fusion protein expressed by nanobody expression vector

[0044] S301, coating antigen: coat the Bp26 protein with the optimal antigen dilution concentration obtained in S1 onto a 96-well ELISA plate and incubate at 4°C overnight;

[0045] S302, blocking: wash three times with PBST solution, 5 min each time, add 100 μL 2.5% skim milk powder, and block at 37°C for 1 h;

[0046] S303, prepare a serum and nanobody mixture: dilute the serum according to the optimal serum dilution obtained in S2, dilute the fusion protein expressed by the nanobody expression vector according to the optimal antibody dilution obtained in S1, prepare a mixture and add it to the ELISA plate, 100 μL per well, incubate at 37° C. for 1 h, and wash three times with PBST;

[0047] S304, color development and termination: TMB color development solution was added and incubated for 15 min, and then 3 M sulfuric acid was used to terminate the reaction. OD 450 Detect absorbance and analyze the results.

[0048] Compared with the prior art, the present invention has the following significant technical effects:

[0049] 1. The present invention is based on the phage display library of Brucella A19 vaccine strain and obtains five specific nanoantibodies for detecting Brucella Bp26 by screening with Bp26 recombinant protein. The specific nanoantibodies include nanoantibody Nb1, nanoantibody Nb2, nanoantibody Nb3, nanoantibody Nb4, and nanoantibody Nb5, which can specifically recognize Brucella outer membrane protein Bp26 and effectively block the binding of Brucella positive serum to Bp26.

[0050] 2. The present invention also provides a method for constructing an expression vector of a Bp26-specific nanoantibody. The expression vector constructed by this construction method can be used to establish a simple and rapid competitive ELISA method to detect Brucella Bp26 antibodies in serum. The detection method is simple to operate, short in time, low in cost, and has good market prospects.

[0051] 3. The specific nanoantibody for detecting Brucella Bp26 prepared by the present invention can also be used to establish sandwich ELISA, colloidal gold and other detection methods to detect brucellosis.

[0052] The present invention is further described in detail below with reference to the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 This is a diagram showing the purification results of Bp26 protein in Example 1 of the present invention.

[0054] Figure 2 This is the result of indirect ELISA in Example 1 of the present invention for detecting Bp26 antibody titer in camel serum.

[0055] Figure 3This is a graph showing the results of detecting a crude extract of Bp26-specific nanoantibodies using the indirect ELISA method of Example 2 of the present invention.

[0056] Figure 4 It is a sequence analysis diagram of Nanobodies Nb1, Nb2, Nb3, Nb4, and Nb5 of Example 2 of the present invention.

[0057] Figure 5 This is a western blot identification diagram of the nanobody of Example 3 of the present invention recognizing Bp26 protein.

[0058] Figure 6 This is the result of determining the affinity between the crude extract of the Nanobody of Example 4 of the present invention and the Bp26 protein.

[0059] Figure 7 This is the result of affinity determination between the nanobody and horseradish peroxidase (HRP) fusion protein of Example 6 of the present invention and the Bp26 protein.

[0060] Figure 8 The competitive ELISA method of Example 7 of the present invention is used to detect Bp26 antibodies in serum. DETAILED DESCRIPTION

[0061] Example 1

[0062] This example is the expression and purification of Brucella Bp26 recombinant protein and the determination of antibody titer in camel serum, and the specific steps are as follows:

[0063] 1. Inducible expression of Bp26 recombinant protein

[0064] The pET32a-Bp26 bacterial suspension stored in the laboratory was inoculated into LB-Amp medium at a ratio of 1 / 1000 and cultured at 37°C and 200 r / min until the logarithmic growth phase (OD 600 The activated bacterial solution was then inoculated into 200 mL of new LB-Amp medium and cultured at 37°C and 200 r / min until the OD 600 0.6, add 200μL 1mM IPTG, and continue to culture at 16℃, 200r / min for 24h. Then divide into 50mL centrifuge tubes, centrifuge at 4℃, 8000r / min for 15min, discard the supernatant, add 1 / 20 volume of buffer A to resuspend the bacteria, and ultrasonically disrupt the bacteria: ultrasonic for 3s, rest for 3s, power 30%, time for 20min; centrifuge at 4℃, 12000r / min for 10min, and separate the supernatant and precipitate.

[0065] 2. Purification of Bp26 protein

[0066] The HIS tag purification gravity column was drained of the protective liquid, and 10 column volumes of buffer A were added to balance the gravity column; the supernatant obtained in step 1 was filtered with a 0.45 μM filter, added to the gravity column, and the supernatant and the medium were fully contacted for 30 minutes, then the flow rate was adjusted to 0.5 mL / min, and the flow-through was collected; 5 to 10 volumes of buffer A were added to wash the column until the A280 absorbance reached the baseline level; 5 to 10 volumes of buffer B were added to wash the column to remove non-specifically adsorbed impurities and collect the effluent until the A280 absorbance reached the baseline level; 0.1 to 0.5 volumes of Elution buffer were used for elution, and the eluate was collected in sections until the A280 absorbance reached the baseline level, and SDS-PAGE was performed. The eluted protein was dialyzed for 36 hours, and the dialysate was replaced every 12 hours. After the dialysis, PEG8000 was used for concentration, and the protein concentration was determined. After aliquoting, it was frozen at -80°C.

[0067] Figure 1 This is the result of the purification of Bp26 protein in this example; wherein, lane 1: flow-through; lane 2: Buffer A washing solution; lanes 3-4: Buffer B washing solution; lanes 5-9: eluted target protein. As shown in the figure, the Bp26 recombinant protein was purified successfully.

[0068] 3. Determination of Bp26 antibody titer in camel serum

[0069] ELISA to detect camel serum titer: 2 μg / mL Bp26 protein was coated on a 96-well ELISA plate at 4°C overnight. Washed three times with PBST, blocked with 2.5% skim milk powder for 1 hour, and washed three times with PBST. Unimmunized camel serum and camel serum immunized three times were mixed at 10 3 , 10 4 , 10 5 , 10 6 , 10 7 Dilute, 100 μL per well, incubate at 37℃ for 1h, wash three times with PBST. Add 1:2000 diluted rabbit anti-camel IgG polyclonal antibody, incubate at 37℃ for 1h; wash three times with PBST, 5min each time. Add 1:4000 diluted horseradish peroxidase labeled goat anti-rabbit IgG, incubate at 37℃ for 1h; wash three times with PBST, 5min each time. Add TMB colorimetric solution and incubate at room temperature for 15min, and terminate the reaction with 3M sulfuric acid. Set the absorbance value of the microplate reader to 450nm, read the value and analyze the immune effect.

[0070] Figure 2 The results of indirect ELISA in this example for detecting Bp26 antibody titer in camel serum show that the specific antibody titer against Bp26 protein reaches 1:10000.

[0071] Example 2

[0072] This example is the screening and verification of specific nano antibodies for detecting Brucella Bp26. The Brucella A19 vaccine strain phage display library used refers to the invention patent CN115043939A; the specific steps for screening specific nano antibodies are:

[0073] 1. Selection of Bp26-specific phage

[0074] Bp26 protein was coated on a 96-well ELISA plate at 10 μg / well, repeated for 3 wells, and a PBS control well was set up. The plate was coated overnight at 4°C. The coating solution was discarded, and the plate was washed three times with PBST for 5 min each time. The plate was blocked with 2.5% skim milk powder and placed at 37°C for 1 h. The blocking solution was discarded, and the plate was washed three times with PBST for 10 min each time. 5×10 10 PFU / well phage, incubate at 37℃ for 2h. Discard the liquid and wash five times with PBST, 5min each time. Add 100μL 0.1M triethylamine (must be prepared before use), let stand at room temperature for 10min, then aspirate the liquid and neutralize with an equal volume of 1MTris-HCl. Take 0.2mL of the selected product to rescue the phage library and measure the titer of the recombinant phage. Then coat with 10 and 5μg / well Bp26 protein, and perform the second and third rounds of panning respectively. The results of the three-round panning titer detection of Bp26-specific phage are shown in Table 1.

[0075] The rescue steps of the phage library are:

[0076] Take 0.2 mL of the selected product and inoculate it into 200 mL of 2×YT / AMP-GLU medium, culture it at 37°C until the logarithmic growth phase, add 20 MOI of helper phage M13K07 and mix evenly, incubate it at 37°C for 30 min, centrifuge it at 3000 g for 15 min at room temperature, discard the supernatant, resuspend the precipitate with 200 mL of 2×YT / AMP-KAN medium, culture it at 37°C for 12 h, centrifuge it at 3000 g for 30 min, collect the supernatant, and add 1 / 5 volume of PEG / Na precooled to 4°C Cl solution, incubate on ice for 6 to 8 hours; centrifuge at 3500g, 4℃ for 30min, discard the supernatant, resuspend the precipitate with 1mL PBS solution, incubate overnight on a shaker at 4℃ for complete dissolution, centrifuge at 4℃, 12000r / min for 15min, collect the supernatant, and use TG1 in the logarithmic growth phase to determine the titer of the recombinant phage; wherein, the preparation method of PEG / NaCl solution is as follows: dissolve 200g PEG6000 and 146g NaCl in water, make the volume to 1L, and then sterilize by high pressure.

[0077] Table 1 Results of three rounds of panning titer detection of Bp26-specific phage.

[0078]

[0079]

[0080] 2. Preparation of Nanobody Crude Extract

[0081] In the last round of selection in step 1 above, 96 phage monoclones were picked and added to 100 μL LB / AMP-GLU medium, cultured in a 96-well cell culture plate, cultured at 37°C, 200 r / min for 8 h, then 10 μL was transferred to a 24-well cell culture plate (1 mL per well, TB medium), and cultured at 37°C until OD 600 When the pH value was 0.6, IPTG was added at a final concentration of 1 mM and culture was continued for 12 h; the cells were collected by centrifugation at 12000 r / min for 5 min, and the cells were lysed by repeated freezing and thawing three times at ultra-low temperatures of -80°C and 37°C, 500 μL PBS was added to resuspend the cells, incubated at 4°C for 2 h, and centrifuged at 12000 r / min for 5 min. The supernatant was collected as the crude nanobody extract.

[0082] 3. Indirect ELISA method to detect crude extracts of nanoantibodies

[0083] Coat 2μg / mL Bp26 recombinant protein and PBS on a 96-well ELISA plate at 4°C overnight. Wash three times with PBST for 5 minutes each time, add 2.5% skimmed milk powder to block for 1 hour, and wash three times with PBST for 5 minutes each time. Add 100μL of the crude nanoantibody extract obtained in step 2 above, incubate at 37°C for 1 hour, and wash five times with PBST for 5 minutes each time. Add diluted (1:3000) mouse anti-HA antibody, incubate at 37°C for 1 hour, and wash three times with PBST for 5 minutes each time. Use HRP-labeled goat anti-mouse IgG, dilute 1:5000 and add to the wells, incubate at 37°C for 1 hour, and wash three times with PBST for 5 minutes each time. After washing, add TMB colorimetric solution and incubate for 15 minutes, and terminate the reaction with 3MH2SO4. The absorbance value of the microplate reader is set to OD 450 , read the values ​​and analyze the test results. Select the positive clones and send them to the company for sequencing, and perform sequence comparison. As a result, five Bp26-specific nanoantibody sequences were obtained, named nanoantibody Nb1, nanoantibody Nb2, nanoantibody Nb3, nanoantibody Nb4, and nanoantibody Nb5.

[0084] Figure 3 This is the result of indirect ELISA detection of Bp26-specific nanobody crude extracts in this example. An OD value more than 3 times greater than the PBS control was judged as positive. The results showed that 84 of the 96 selected clones were positive clones.

[0085] Figure 4It is an amino acid sequence analysis diagram of Bp26-specific nanoantibodies Nb1, Nb2, Nb3, Nb4, and Nb5 of this embodiment. As shown in the figure, nanoantibody Nb1, nanoantibody Nb2, nanoantibody Nb3, nanoantibody Nb4, and nanoantibody Nb5 all include four framework regions FR1, FR2, FR3, FR4 and three complementary determining regions CDR1, CDR2, and CDR3, and the arrangement order of the four framework regions and the three complementary determining regions is FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4;

[0086] For Nanobody Nb1: the amino acid sequence of FR1 is shown in SEQ ID NO.11, the amino acid sequence of FR2 is shown in SEQ ID NO.12, the amino acid sequence of FR3 is shown in SEQ ID NO.13, the amino acid sequence of FR4 is shown in SEQ ID NO.14, the amino acid sequence of CDR1 is shown in SEQ ID NO.15, the amino acid sequence of CDR2 is shown in SEQ ID NO.16, and the amino acid sequence of CDR3 is shown in SEQ ID NO.17;

[0087] For Nanobody Nb2: the amino acid sequence of FR1 is shown in SEQ ID NO.18, the amino acid sequence of FR2 is shown in SEQ ID NO.19, the amino acid sequence of FR3 is shown in SEQ ID NO.20, the amino acid sequence of FR4 is shown in SEQ ID NO.21, the amino acid sequence of CDR1 is shown in SEQ ID NO.22, the amino acid sequence of CDR2 is shown in SEQ ID NO.23, and the amino acid sequence of CDR3 is shown in SEQ ID NO.24;

[0088] For Nanobody Nb3: the amino acid sequence of FR1 is shown in SEQ ID NO.25, the amino acid sequence of FR2 is shown in SEQ ID NO.26, the amino acid sequence of FR3 is shown in SEQ ID NO.27, the amino acid sequence of FR4 is shown in SEQ ID NO.28, the amino acid sequence of CDR1 is shown in SEQ ID NO.29, the amino acid sequence of CDR2 is shown in SEQ ID NO.30, and the amino acid sequence of CDR3 is shown in SEQ ID NO.31;

[0089] For Nanobody Nb4: the amino acid sequence of FR1 is shown in SEQ ID NO.32, the amino acid sequence of FR2 is shown in SEQ ID NO.33, the amino acid sequence of FR3 is shown in SEQ ID NO.34, the amino acid sequence of FR4 is shown in SEQ ID NO.35, the amino acid sequence of CDR1 is shown in SEQ ID NO.36, the amino acid sequence of CDR2 is shown in SEQ ID NO.37, and the amino acid sequence of CDR3 is shown in SEQ ID NO.38;

[0090] For Nanobody Nb5: the amino acid sequence of FR1 is shown in SEQ ID NO.39, the amino acid sequence of FR2 is shown in SEQ ID NO.40, the amino acid sequence of FR3 is shown in SEQ ID NO.41, the amino acid sequence of FR4 is shown in SEQ ID NO.42, the amino acid sequence of CDR1 is shown in SEQ ID NO.43, the amino acid sequence of CDR2 is shown in SEQ ID NO.44, and the amino acid sequence of CDR3 is shown in SEQ ID NO.45.

[0091] Example 3

[0092] This example is a western blot to verify the specificity of the selected nanobody.

[0093] Take 10 μL of 1 μg / μL Bp26 protein, add Loading buffer and mix well, and place in a metal bath at 100℃ for 10 minutes. After loading, start electrophoresis and set the conditions: 80V constant voltage for 30 minutes, 120V constant voltage for 90 minutes. Transfer the membrane using the wet transfer method. After transfer, block with 5% skim milk powder for 1 hour and wash three times with PBST, each for 5 minutes. The crude extract of the nanobody is used as the primary antibody, incubated at room temperature for 1 hour, and washed three times with PBST; incubate the mouse anti-HA tag antibody at room temperature for 1 hour, and wash three times with PBST; incubate the HRP-goat anti-mouse IgG at room temperature for 1 hour and wash three times with PBST. ECL luminescent liquid is used for color development, imaging and analysis of the results.

[0094] Figure 5 This is a western blot identification diagram of the nanobody in this example recognizing the Bp26 protein. The results show that the crude extract of the nanobody can specifically bind to the Brucella Bp26 protein.

[0095] Example 4

[0096] This example is an indirect ELISA method to detect the affinity of the selected nanobody crude extract, and the specific steps are:

[0097] (1) Dilute Bp26 protein to 2 μg / mL and coat a 96-well ELISA plate at 4°C overnight;

[0098] (2) Wash the plate three times with PBST and block with 2.5% skim milk powder at 37°C for 1 h;

[0099] (3) The crude extract of the nanobody was diluted in a ratio of 1:10 and 1:10. 2 , 1:10 3 , 1:10 4 dilution, add 100 μL to each well, incubate at 37°C for 1 h, and wash the plate three times with PBST;

[0100] (4) Add mouse anti-HA tag antibody and incubate for 1 h, then wash the plate three times with PBST;

[0101] (5) Add HRP-goat anti-mouse IgG and incubate for 1 h, then wash the plate three times with PBST;

[0102] (6) Add TMB substrate colorimetric solution and incubate for 15 min, then terminate the reaction with stop solution. 450 Read the values ​​and analyze the experimental results.

[0103] Figure 6 The results of the determination of the affinity between the crude extracts of the nanobodies of this example and Bp26 show that the affinity between the crude extracts of the five nanobodies and Bp26 is very high, among which the affinity between the crude extract of Nb5 and Bp26 is the highest.

[0104] Example 5

[0105] This embodiment is a method for constructing a nanobody and horseradish peroxidase (HRP) fusion protein expression vector, which comprises the following steps:

[0106] (1) Construction of recombinant eukaryotic expression vector: PCR amplification of the gene sequences of Nb1, Nb2, Nb3, Nb4, and Nb5 using TAKARA primestar GXL enzyme, and recovery and purification; double digestion of the target fragment and the pCMV-HRP expression vector with PstI and Not I enzymes, ligation of the target fragment with the plasmid, transformation of the ligation product into BL21 competent cells, plating, picking single clones and performing PCR verification, and sending them to the company for sequencing after successful verification;

[0107] PCR amplification reaction system: 5X PrimeSTARGXL Buffer 10 μL, dNTP Mixture 4 μL, primer F 1 μL, primer R 1 μL, PrimeSTARGXL DNA polymerase 1 μL, template 1 μL, ddH2O 32 μL;

[0108] PCR amplification reaction program: 98°C for 10 s, 60°C for 15 s, 68°C for 24 s, for 30 cycles.

[0109] (2) Plasmids were extracted from the positive samples that were sequenced correctly to obtain endotoxin-free pCMV-Nb1-HRP, pCMV-Nb2-HRP, pCMV-Nb3-HRP, pCMV-Nb4-HRP, and pCMV-Nb5-HRP plasmids.

[0110] (3) HEK-293T cells were plated on a 12-well plate. When the cells were 70% to 80% full, ThermoTurboFect transfection reagent was used. The system was: 4 μL TurboFect, 1 μg plasmid, 200 μL serum-free DMEM medium. After mixing evenly, the mixture was incubated at room temperature for 15 min. HEK-293T cells were added. After 72 h, the supernatant was collected to obtain Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP fusion proteins for activity verification.

[0111] Example 6

[0112] This example uses an ELISA method to detect the affinity of Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP fusion proteins with Bp26 protein. The specific steps are as follows:

[0113] (1) 10 μg / mL Bp26 protein was coated on a 96-well ELISA plate at 4°C overnight;

[0114] (2) Wash the plate three times with PBST, block with 2.5% skim milk powder at 37°C for 1 h, and wash the plate three times with PBST;

[0115] (3) Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP were diluted 4, 16, 64, 256, 1024, and 4096 times, respectively, added to the ELISA plate, incubated at 37°C for 1 h, and washed three times with PBST;

[0116] (4) Add TMB substrate colorimetric solution and incubate for 15 min. Stop the reaction with stop solution. 450 Read the values ​​and analyze the experimental results.

[0117] Figure 7 The results of the affinity determination of Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, Nb5-HRP and Bp26 in this example show that Nb2-HRP has the highest affinity for Bp26.

[0118] Example 7

[0119] The present embodiment is the application of nano antibody expression vector, and the fusion protein expressed by the nano antibody expression vector can be used for setting up the competitive ELISA method to detect Brucella Bp26 antibody. The fusion protein expressed by the nano antibody expression vector used in the present embodiment is Nb2-HRP, and the structure of the competitive ELISA method comprises the following steps:

[0120] 1. Determine the optimal antigen-antibody working concentration by chessboard method

[0121] (1) Antigen coating: dilute the Bp26 protein to 1, 2, or 4 μg / mL and coat on the ELISA plate at 4°C overnight;

[0122] (2) Blocking: Wash three times with PBST solution, 5 min each time, add 100 μL of 2.5% skim milk powder, block at 37°C for 1 h, and wash three times with PBST;

[0123] (3) Antibody incubation: Nb2-HRP was diluted 2, 4, 8, 16, 32, 64, and 128 times, added to the ELISA plate, incubated at 37°C for 1 h, and washed three times with PBST;

[0124] (4) Color development and termination: Add 100 μL of TMB color development solution and incubate at room temperature for 15 min. Terminate the reaction with 50 μL of 3 M sulfuric acid and read the absorbance at 450 nm.

[0125] The test results were analyzed and it was determined that 2 μg / mL was the optimal antigen coating concentration and 1:32 was the optimal antibody dilution concentration.

[0126] 2. Determine the serum dilution for competitive ELISA method

[0127] (1) Antigen coating: 2 μg / mL Bp26 protein was coated onto a 96-well ELISA plate at 4°C overnight;

[0128] (2) Blocking: Wash three times with PBST solution, add 100 μL of 2.5% skim milk powder, block at 37°C for 1 h, and wash three times with PBST;

[0129] (3) Serum dilution: Select four samples of positive serum and negative serum, dilute them at 1:5, 1:10, 1:15, and 1:20, and mix them with 1:32 diluted Nb2-HRP. Add 100 μL of the mixture to each well, incubate at 37°C for 1 h, and wash three times with PBST.

[0130] (4) Color development and termination: Incubate with TMB color development solution at room temperature for 15 min, and terminate the reaction with 3 M sulfuric acid. Read the absorbance at 450 nm.

[0131] The test results were analyzed and the optimal serum dilution for the competitive ELISA method was determined to be 1:10.

[0132] 3. Establishment of competitive ELISA method based on Nb2-HRP

[0133] (1) Antigen coating: 2 μg / mL Bp26 protein was coated onto a 96-well ELISA plate and incubated at 4°C overnight;

[0134] (2) Blocking: Wash three times with PBST solution, 5 min each time, add 100 μL of 2.5% skim milk powder, block at 37°C for 1 h, and wash three times with PBST;

[0135] (3) Preparation of serum and nanoantibody mixture: serum was diluted 1:10, Nb2-HRP was diluted 1:32, the mixture was prepared and added to the ELISA plate, 100 μL per well, incubated at 37°C for 1 h, and washed three times with PBST;

[0136] (4) Color development and termination: Add TMB color development solution and incubate for 15 min, then terminate the reaction with 3 M sulfuric acid. 450 Detect the absorbance and analyze the test results.

[0137] Figure 8 1 is a result diagram of the competitive ELISA method based on Nb2-HRP for detecting Bp26 antibodies in serum in this embodiment. The results show that Nb2-HRP can effectively block the binding of Brucella positive serum to Bp26.

[0138] The expression vector of the Bp26-specific nanobody of the present invention can also be used to establish sandwich ELISA, colloidal gold test strips and other detection methods to detect brucellosis.

[0139] The above is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent change made to the above embodiment according to the technical essence of the invention still falls within the protection scope of the technical solution of the present invention.

Claims

1. A specific nanobody for detecting Brucella Bp26, characterized in that, The nanobodies include five types, respectively named as nanobody Nb1, nanobody Nb2, nanobody Nb3, nanobody Nb4, and nanobody Nb5; The nucleotide sequence of the nanobody Nb1 is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2; The nucleotide sequence of the nanobody Nb2 is shown in SEQ ID NO.3, and the amino acid sequence is shown in SEQ ID NO.4; The nucleotide sequence of the nanobody Nb3 is shown in SEQ ID NO.5, and the amino acid sequence is shown in SEQ ID NO.6; The nucleotide sequence of the nanobody Nb4 is shown in SEQ ID NO.7, and the amino acid sequence is shown in SEQ ID NO.8; The nucleotide sequence of the nanobody Nb5 is shown in SEQ ID NO.9, and the amino acid sequence is shown in SEQ ID NO.

10.

2. A method for constructing an expression vector for a specific nano antibody for detecting Brucella Bp26 according to claim 1, characterized in that: The method is: The gene sequence of the Bp26-specific nanoantibody was inserted into the pCMV-HRP vector through the two restriction sites of Pst I and Not I, and the recombinant plasmids were constructed respectively. The correctness of the recombinant plasmids was verified by PCR and sequencing. The endotoxin-free pCMV-Nb1-HRP, pCMV-Nb2-HRP, pCMV-Nb3-HRP, pCMV-Nb4-HRP, and pCMV-Nb5-HRP recombinant plasmids were extracted respectively. HEK-293T cells were plated in 12-well plates. When the cells were 70% to 80% full, the cells were plated using Thermo The TurboFect transfection reagent mixed with the recombinant plasmid was transfected into HEK-293T cells, and the supernatant was collected after 72 hours to obtain Nb1-HRP, Nb2-HRP, Nb3-HRP, Nb4-HRP, and Nb5-HRP fusion proteins, respectively; the Bp26-specific nanoantibodies include nanoantibody Nb1, nanoantibody Nb2, nanoantibody Nb3, nanoantibody Nb4, and nanoantibody Nb5.

3. An application of the expression vector constructed by the construction method according to claim 2, characterized in that: The fusion protein expressed by the expression vector can be used to construct a competitive ELISA method for detecting Brucella Bp26 antibodies for non-disease diagnosis purposes.

Citation Information

Cited By

  • Brucella recombinant antigen protein, Brucella recombinant antigen protein nano-particles, and preparation method and application of Brucella recombinant antigen protein nano-particles

    CN120865432A